Trastuzumab Deruxtecan Shows Promise in HER2 Targeted Therapy

A study with a small sample size revealed that trastuzumab deruxtecan showed promising activity in multiple HER2-expressing or HER2-mutant solid tumors.

Source: CancerNetwork - March 27, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news